Petros Pharmaceuticals, Inc. (PTPI)
| Market Cap | 23.34M |
| Revenue (ttm) | 12.93M |
| Net Income (ttm) | n/a |
| Shares Out | 9.80M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,462,610 |
| Open | 1.80 |
| Previous Close | 1.64 |
| Day's Range | 1.68 - 1.92 |
| 52-Week Range | 1.56 - 5.96 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About PTPI
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based...
Financial Performance
In 2020, PTPI's revenue was $9.56 million, a decrease of -38.63% compared to the previous year's $15.58 million. Losses were -$20.59 million, -36.68% less than in 2019.
Financial StatementsNews
Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced register...
Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements w...
Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fad...
Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Incre...
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results fo...
Petros Pharmaceuticals to Present at Two Upcoming August Conferences
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady...
Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit
New Jersey and Pennsylvania--(Newsfile Corp. - August 11, 2021) - Petros Pharmaceuticals (NASDAQ: PTPI) today announced that Fady Boctor, President, Chief Commercial Officer will be attending the Q3 Vir...
Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021
NEW YORK, July 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady...
Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021
NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady ...
Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase...
NEW YORK, May 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the...
Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Investor ...
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the ...
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovati...
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused...
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.
Some Great News for Potential Alzheimer’s Treatment
It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study update from eve...
Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment
Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) ...
Why Neurotrope Is Plunging On Heavy Volume
Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.
Neurotrope Sees Hammer Chart Pattern: Time to Buy?
Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.
Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?
Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.
Two Very Speculative Biotechs With Promising Alzheimer’s Treatment Hopefuls
The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.
Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?
Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting late-stage...